Vanguard Global Advisers
SGP

Vanguard Global Advisers’s SpyGlass Pharma SGP Stock Holding History

Vanguard Global Advisers’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Sell
4,627
-300
-6% -$6.51K ﹤0.01% 2768
2026
Q1 		$128K Buy
+4,927
New +$133K ﹤0.01% 2632

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Vanguard Global Advisers's SGP Position: Q2 2026 in Review

Vanguard Global Advisers reduced its SpyGlass Pharma (SGP) stake by 6.1% in Q2 2026, selling an estimated $6.51K and leaving 4,627 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #2768.

Vanguard Global Advisers first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. The position peaked at $128K in Q1 2026. 43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Vanguard Global Advisers held 4,627 shares of SpyGlass Pharma worth $103K as of Q2 2026.
  • Vanguard Global Advisers sold 300 SpyGlass Pharma shares in Q2 2026, an estimated $6.51K.
  • SpyGlass Pharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2768 holding.
  • Vanguard Global Advisers first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's SpyGlass Pharma position peaked at $128K in Q1 2026.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.